BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss ...

The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.

February 28, 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble ...